New drug shows improvement in survival of advanced thyroid cancer
Description: In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.
The global study, led by Steven Sherman, M.D., associate vice-provost for Clinical Research, and professor and chair, Endocrine Neoplasia and Hormonal Disorders, is published in the New England Journal of Medicine, and could offer a new treatment paradigm for a group of patients for whom, until recently, there has been no new effective treatment since the 1940s.
According to the American Cancer Society, 62,450 people will be diagnosed with thyroid cancer in 2015 and 1,950 will die from the disease. It’s the fastest growing cancer type, says Sherman, with rates of refractory disease also on the rise. Until recent therapeutic advances, historically, radioactive iodine has been the only treatment available to patients with metastatic thyroid disease.
For patients with advanced and metastatic disease, lenvatinib and this class of drugs is the first potential for improved overall survival. A number of follow up studies with lenvatinib are in development, including in other types of thyroid cancers, and in combination with other novel therapies for radioiodine refractory patients.
Shared By : mdanderson
Posted on : 02/11/15
Added : 5 years ago